Local recurrence of prostate cancer after external beam radiotherapy:: Early experience of salvage therapy using high-intensity focused ultrasonography

被引:180
作者
Gelet, A [1 ]
Chapelon, JY
Poissonnier, L
Bouvier, R
Rouvière, O
Curiel, L
Janier, M
Vallancien, G
机构
[1] Hop Edouard Herriot, Dept Urol & Transplantat, F-69437 Lyon 03, France
[2] French Inst Hlth & Med Res, INSERM, Lyon, France
[3] CERMEP, Lyon, France
[4] Inst Mutualiste Montsouris, Dept Urol, Paris, France
关键词
D O I
10.1016/j.urology.2004.01.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To evaluate the efficacy and safety of a salvage therapy using transrectal high-intensity focused ultrasonography (HIFU) for locally recurrent prostate cancer after external beam radiotherapy. Methods. All patients were treated with HIFU under general or spinal anesthesia. Specific parameters were progressively defined to avoid any rectal damage. Patient follow-up included sextant biopsy and prostate-specific antigen (PSA) measurement. Results. A total of 7 1 patients were included in this series. The main baseline characteristics before HIFU were mean age 67 +/- 5.86 years, mean prostate volume 21.4 +/- 11.1 cm(3), and mean PSA level 7.73 +/- 8.10 ng/mL. All biopsies were positive, with a pre-HIFU Gleason score of 2 to 6 in 24 patients, 7 in 13 patients, and 8 to 10 in 34 patients. The mean patient follow-up was 14.8 months (range 6 to 86). After HIFU treatment, 57 (80%) of the 71 patients had negative biopsies, and 43 (61%) of 71 had a nadir PSA level of less than 0.5 ng/mL. The nadir level was obtained within 3 months. At the last follow-up, 44% of the patients had no evidence of any disease progression. The adverse events related to HIFU included rectourethral fistula in 6%, grade 3 incontinence in 7%, and bladder neck stenosis in 17%. No rectal injury occurred with the use of specific parameters. Conclusions. HIFU appears to be a promising treatment option with a curative chance for patients with local recurrence after external beam radiotherapy. The HIFU-related morbidity was lower than the morbidity reported after other types of salvage therapy, leading to a favorable risk/benefit ratio. (C) 2004 Elsevier Inc.
引用
收藏
页码:625 / 629
页数:5
相关论文
共 13 条
  • [1] Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer
    Amling, CL
    Lerner, SE
    Martin, SK
    Slezak, JM
    Blute, ML
    Zincke, H
    [J]. JOURNAL OF UROLOGY, 1999, 161 (03) : 857 - 862
  • [2] Pretreatment predictors of time to cancer specific death after prostate specific antigen failure
    D'Amico, AV
    Cote, K
    Loffredo, M
    Renshaw, AA
    Chen, MH
    [J]. JOURNAL OF UROLOGY, 2003, 169 (04) : 1320 - 1324
  • [3] Cryoablation of localized prostate cancer -: Experience in 48 cases, PSA and biopsy results
    Derakhshani, P
    Neubauer, S
    Braun, M
    Zumbé, J
    Heidenreich, A
    Engelmann, U
    [J]. EUROPEAN UROLOGY, 1998, 34 (03) : 181 - 187
  • [4] Transrectal high-intensity focused ultrasound:: Minimally invasive therapy of localized prostate cancer
    Gelet, A
    Chapelon, JY
    Bouvier, R
    Rouvière, O
    Lasne, Y
    Lyonnet, D
    Dubernard, JM
    [J]. JOURNAL OF ENDOUROLOGY, 2000, 14 (06) : 519 - 528
  • [5] Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: Preliminary results
    Gelet, A
    Chapelon, JY
    Bouvier, R
    Pangaud, C
    Lasne, Y
    [J]. JOURNAL OF UROLOGY, 1999, 161 (01) : 156 - 162
  • [6] Salvage brachytherapy for localized prostate cancer after radiotherapy failure
    Grado, GL
    Collins, JM
    Kriegshauser, JS
    Balch, CS
    Grado, MM
    Swanson, GP
    Larson, TR
    Wilkes, MM
    Navickis, RJ
    [J]. UROLOGY, 1999, 53 (01) : 2 - 10
  • [7] Conformal external beam treatment of prostate cancer
    Hanks, GE
    Hanlon, AL
    Schultheiss, TE
    Freedman, GM
    Hunt, M
    Pinover, WH
    Movsas, B
    [J]. UROLOGY, 1997, 50 (01) : 87 - 92
  • [8] Lee F, 1997, ANTICANCER RES, V17, P1511
  • [9] Miller RJ, 1996, CANCER, V77, P1510, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1510::AID-CNCR13>3.0.CO
  • [10] 2-2